Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | CN | 31 Oct 2023 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | US | 03 May 2022 |